GeoVax Labs GOVX

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies for infectious diseases and solid tumor cancers using proprietary platforms. Its primary near-term strategic focus is advancing GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox, and other poxviruses, under an expedited regulatory pathway in Europe. The company also develops Gedeptin®, an oncolytic solid tumor gene-directed therapy for advanced head and neck cancer, and GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine for immunocompromised patients and booster use in healthy adults.

GeoVax generates revenue through the development and potential commercialization of its vaccine and immunotherapy candidates, supported by internal progress and selective external licensing and partnership arrangements. The company collaborates with academic, governmental, and industry partners to validate technologies, support development, and enhance pipeline value. Revenue is pursued via regulatory approval pathways and commercialization efforts for its lead programs, including GEO-MVA, Gedeptin®, and GEO-CM04S1, targeting public health, biodefense, and oncology markets.

The company operates through the following segments:

• Infectious Diseases: This segment focuses on the development of vaccines for viral threats including mpox, smallpox, and COVID-19. Key programs include GEO-MVA for poxviruses and GEO-CM04S1 for coronavirus prevention and boosting. The segment leverages the Modified Vaccinia Ankara (MVA) platform to induce broad immune responses involving both antibodies and T-cells.

• Oncology: This segment develops immunotherapies for solid tumors, centered on Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT). Gedeptin® uses a replication-deficient adenovirus vector to deliver tumor-specific genes that convert prodrugs into active antitumor agents locally. The technology is being evaluated in combination with immune checkpoint inhibitors for squamous cell head and neck cancer, with a Phase 2 trial planned for initiation in the first half of 2027.

GeoVax holds a differentiated position in the biotechnology sector through its proprietary MVA-based vaccine platform and GDEPT oncology technology, addressing supply constraints in orthopoxvirus vaccines and immune evasion in solid tumors. The company competes with established vaccine developers and gene therapy firms but distinguishes itself via dual-use public health and biodefense applications, particularly for GEO-MVA, and its ability to target multiple antigens in GEO-CM04S1. Its orphan drug designation for Gedeptin® and engagements with agencies like the EMA, BARDA, and NIH support its strategic advancement in niche therapeutic areas.

GeoVax serves government health agencies, public health organizations, immunocompromised patient populations, and oncology treatment centers. Specific customers or partners referenced include the National Institutes of Health (NIH), Emory University, City of Hope (COH), the Biomedical Advanced Research Development Authority (BARDA), and the U. S. Food and Drug Administration (FDA) through grant programs and regulatory collaborations. The company also works with clinical trial sites and academic institutions to advance its pipeline.